{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:15:41Z","timestamp":1762521341277,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T00:00:00Z","timestamp":1269648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00296-010-1424-3","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T05:50:21Z","timestamp":1269582621000},"page":"1147-1151","source":"Crossref","is-referenced-by-count":11,"title":["TNF-alpha antagonist therapy modify the tuberculin skin test response"],"prefix":"10.1007","volume":"31","author":[{"given":"Tulin","family":"Cagatay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeki","family":"Kilicaslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penbe","family":"Cagatay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munevver","family":"Mertsoylu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziya","family":"Gulbaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyhan","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Pur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevil","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,27]]},"reference":[{"key":"1424_CR1","volume-title":"WHO report 2007: global tuberculosis control: surveillance, planning, financing","author":"World Health Organization","year":"2007","unstructured":"World Health Organization (2007) WHO report 2007: global tuberculosis control: surveillance, planning, financing. WHO, Geneva"},{"key":"1424_CR2","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/ndt\/gfl416","volume":"21","author":"U Sester","year":"2006","unstructured":"Sester U, Junker H, Junker H et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 21:3258\u20133268","journal-title":"Nephrol Dial Transplant"},{"key":"1424_CR3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","volume":"194","author":"OY Saliu","year":"2006","unstructured":"Saliu OY, Sofer C, Stein DS et al (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486\u2013492","journal-title":"J Infect Dis"},{"key":"1424_CR4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.bor.0000127594.92432.7c","volume":"16","author":"HC Dukes","year":"2004","unstructured":"Dukes HC (2004) Infectious complications of treatment with biologic agents: infectious arthritis and immune dysfunction. Curr Opin Rheumatol 16:393\u2013398","journal-title":"Curr Opin Rheumatol"},{"key":"1424_CR5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.imlet.2006.08.002","volume":"107","author":"M Vukmanovic-Stejic","year":"2006","unstructured":"Vukmanovic-Stejic M, Reed JR, Lacy KE et al (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93\u2013101","journal-title":"Immunol Lett"},{"key":"1424_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02715694","volume":"3","author":"MG Helliwell","year":"1984","unstructured":"Helliwell MG, Panayi GS, Unger A (1984) Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol 3:39\u201345","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"1424_CR7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.62.suppl_2.ii2","volume":"62","author":"DE Furst","year":"2003","unstructured":"Furst DE, Breedveld FC, Kalden JR et al (2003) Updated consensus statement on biological agents for treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 62(Suppl 2):2\u20139","journal-title":"Ann Rheum Dis"},{"key":"1424_CR8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"Thoracic Society Standards of Care Committee","year":"2005","unstructured":"Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-\u03b1 treatment. Thorax 60:800\u2013805","journal-title":"Thorax"},{"key":"1424_CR9","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","volume":"8","author":"H Hamdi","year":"2006","unstructured":"Hamdi H, Mariette X, Godot V et al (2006) The RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114","journal-title":"Arthritis Res Ther"},{"key":"1424_CR10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2005.040055","volume":"65","author":"BE Joven","year":"2006","unstructured":"Joven BE, Almod\u00f3var R, Galindo M et al (2006) Does anti-tumour necrosis factor \u03b1 treatment modify the tuberculin TST response? Ann Rheum Dis 65:699","journal-title":"Ann Rheum Dis"},{"key":"1424_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1371\/journal.pone.0000183","volume":"2","author":"PC Hill","year":"2007","unstructured":"Hill PC, Jeffries DJ, Brookes RH et al (2007) Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoSONE 2:183","journal-title":"PLoSONE"},{"key":"1424_CR12","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.rmed.2006.02.032","volume":"100","author":"H Kunst","year":"2006","unstructured":"Kunst H (2006) Diagnosis of latent tuberculosis infection: the potential role of new technologies. Respir Med 100:2098\u20132106","journal-title":"Respir Med"},{"key":"1424_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4081\/monaldi.2005.634","volume":"63","author":"LR Codecasa","year":"2005","unstructured":"Codecasa LR, Ferrarese M, Penati V et al (2005) Comparison of tuberculin skin test and Quantiferon immunological assay for latent tuberculosis infection. Monaldi Arch Chest Dis 63:158\u2013162","journal-title":"Monaldi Arch Chest Dis"},{"key":"1424_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/ard.48.2.108","volume":"48","author":"MD Smith","year":"1989","unstructured":"Smith MD, Smith A, O\u2019Donnell J et al (1989) Impaired delayed type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy. Ann Rheum Dis 48:108\u2013113","journal-title":"Ann Rheum Dis"},{"key":"1424_CR15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0952-7915(99)80067-3","volume":"11","author":"KM Kerksiek","year":"1999","unstructured":"Kerksiek KM, Pamer EG (1999) T cell responses to bacterial infections. Curr Opin Immunol 11:400\u2013405","journal-title":"Curr Opin Immunol"},{"key":"1424_CR16","doi-asserted-by":"crossref","first-page":"30021","DOI":"10.1128\/IAI.59.9.3021-3025.1991","volume":"59","author":"T Ogawa","year":"1991","unstructured":"Ogawa T, Uchida H, Kusumoto Y et al (1991) Increase in tumor necrosis factor \u03b1 and interleukin-6 secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun 59:30021\u201330025","journal-title":"Infect Immun"},{"key":"1424_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0966-842X(00)88864-2","volume":"3","author":"LE Bermudez","year":"1995","unstructured":"Bermudez LE, Kaplan G (1995) Recombinant cytokines for controlling mycobacterial infections. Trends Microbiol 3:22\u201327","journal-title":"Trends Microbiol"},{"key":"1424_CR18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","volume":"56","author":"V Kindler","year":"1989","unstructured":"Kindler V, Sappino AP, Grau GE et al (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731\u2013740","journal-title":"Cell"},{"key":"1424_CR19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/IAI.58.1.269-271.1990","volume":"58","author":"IEA Flesch","year":"1990","unstructured":"Flesch IEA, Kaufmann SHE (1990) Activation of tuberculostatic macrophage functions by interferon gamma, interleukin 4 and tumor necrosis factor. Infect Immun 58:269\u2013271","journal-title":"Infect Immun"},{"key":"1424_CR20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2249.2001.01439.x","volume":"123","author":"R Hussain","year":"2001","unstructured":"Hussain R, Shiratsuchi H, Phillips M et al (2001) Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-\u03b1 (TNF-\u03b1) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes\u2014implications for pathogenesis. Clin Exp Immunol 123:210\u2013218","journal-title":"Clin Exp Immunol"},{"key":"1424_CR21","first-page":"2158","volume":"34","author":"H Pachot","year":"2007","unstructured":"Pachot H, Arnaud B, Marrote H et al (2007) Increased tumor necrosis factor-\u03b1 mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 34:2158\u20132161","journal-title":"J Rheumatol"},{"key":"1424_CR22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/ar1465","volume":"7","author":"H Marotte","year":"2005","unstructured":"Marotte H, Maslinski W, Miossec P (2005) Circulating tumour necrosis factor-\u03b1 bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 7:149\u2013155","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-010-1424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-010-1424-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-010-1424-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:26:32Z","timestamp":1739989592000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-010-1424-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,27]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s00296-010-1424-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2010,3,27]]}}}